ICON PLC

NASDAQ ICLR

Download Data

ICON PLC EBITDA for the quarter ending March 31, 2024: USD 453.14 M

ICON PLC EBITDA is USD 453.14 M for the quarter ending March 31, 2024, a 17.98% change year over year. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, measures a company's operating performance by excluding non-operating expenses.
  • ICON PLC EBITDA for the quarter ending March 31, 2023 was USD 384.10 M, a 17.04% change year over year.
  • ICON PLC EBITDA for the quarter ending March 31, 2022 was USD 328.16 M, a 145.96% change year over year.
  • ICON PLC EBITDA for the quarter ending March 31, 2021 was USD 133.42 M, a 7.23% change year over year.
  • ICON PLC EBITDA for the quarter ending March 31, 2020 was USD 124.42 M, a -1.75% change year over year.
NASDAQ: ICLR

ICON PLC

CEO Dr. Steven A. Cutler MBA, Ph.D.
IPO Date May 15, 1998
Location Ireland
Headquarters South County Business Park, Dublin, Ireland, 18
Employees 41,150
Sector Healthcare
Industry Diagnostics & research
Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Similar companies

CRL

Charles River Laboratories

NA

NA

LH

Laboratory Corporation of America Holdings

NA

NA

NEOG

Neogen Corporation

NA

NA

QGEN

Qiagen NV

NA

NA

TWST

Twist Bioscience Corp

NA

NA

WAT

Waters Corporation

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email